iBio, Inc. (IBIO) - Q1 2026 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2025 (Fiscal Q1 2026). iBio, Inc. is a preclinical-stage biotechnology company utilizing an AI-driven drug discovery platform to develop precision antibodies for cardiometabolic and obesity indications. The company operates as a single reportable segment and is currently focused on advancing its lead candidates, IBIO-610 (Activin E inhibitor) and IBIO-600 (Myostatin inhibitor), toward clinical trials anticipated to commence in early 2027.
Key Financial Metrics
| Metric (in thousands, except per share) | Q1 2026 (Ended Sep 30, 2025) | Q1 2025 (Ended Sep 30, 2024) |
|---|---|---|
| Revenue | $100 | $0 |
| Operating Expenses | $6,051 | $4,106 |
| Net Loss | $(5,720) | $(3,989) |
| Loss Per Share (Basic & Diluted) | $(0.11) | $(0.46) |
| Cash & Cash Equivalents | $28,111 | $11,261 (Total cash incl. restricted) |
| Investments in Debt Securities | $21,456 | $0 |
| Total Current Assets | $50,772 | $9,721 |
| Total Liabilities | $8,116 | $8,305 |
| Stockholders' Equity | $56,039 | $14,880 |
Cash Flow Highlights: Net cash used in operating activities was $5.7 million. Net cash provided by financing activities was $46.7 million, primarily driven by a $50 million underwritten public offering in August 2025. Net cash used in investing activities was $21.5 million, largely due to the purchase of debt securities.
Material Changes vs. Prior Period
- Liquidity Position: Total liquid assets (cash, cash equivalents, and debt securities) increased significantly from approximately $11.3 million in the prior year to $49.6 million, following the August 2025 capital raise.
- Revenue: The company recognized $100,000 in revenue from a collaborative partner, compared to zero in the prior year.
- Operating Expenses: Total operating expenses increased by approximately $1.9 million ($6.1M vs. $4.1M). Research and Development (R&D) expenses rose by $2.2 million to $3.6 million due to increased spending on consultants and personnel to advance IBIO-600 and IBIO-610. General and Administrative (G&A) expenses decreased by $0.3 million.
- Debt Securities: The company invested $21.5 million in government-issued debt securities (treasury bills/notes) during the quarter, which were not present in the prior period.
Outlook, Risks, and Management Commentary
- Capital Raise: In August 2025, the company closed an underwritten public offering raising gross proceeds of approximately $50 million (net proceeds ~$46.4 million). This included the sale of pre-funded warrants and accompanying Series G and H warrants.
- Liquidity & Going Concern: Management believes the current cash position of ~$49.6 million is sufficient to fund operations for at least 12 months from the filing date. However, the company notes a history of significant losses and negative cash flows, which historically raised substantial doubt about its ability to continue as a going concern. The recent capital raise mitigates this risk for the near term.
- Pipeline Progress:
- IBIO-610: Preclinical data in mice showed 8.9% body weight reduction and 26% fat mass reduction with no lean mass loss. Combination therapy with semaglutide showed 35.3% weight loss. Non-human primate (NHP) PK studies indicated a half-life of ~33 days, projecting a human half-life of 47-100 days.
- IBIO-600: NHP studies showed a half-life of 40-52 days. The company is advancing CMC and toxicology studies and seeking a development partner.
- Risks:
- Government Shutdown: The filing highlights risks associated with the U.S. federal government shutdown (as of Sept 30, 2025), which could delay FDA reviews, IND approvals, and access to capital markets.
- Profitability: The company does not anticipate generating significant revenue for several years and expects to continue incurring losses.
- Dilution: Significant potential dilution exists from outstanding warrants, including Series G and H warrants from the 2025 offering.
Investor Verification Checklist
- Cash Runway: Verify the burn rate against the $49.6 million liquid asset balance to confirm the 12-month liquidity assertion.
- Capital Structure: Review the terms of the Series G and H warrants issued in August 2025, specifically the "Trial Initiation Milestone" expiration triggers and potential dilution impact.
- Regulatory Timeline: Monitor the impact of the federal government shutdown on the FDA's ability to review the company's planned IND applications for IBIO-610 and IBIO-600.
- Partnership Status: Confirm progress on securing a development partner for IBIO-600, as management indicated this is a strategic priority.
- Debt Obligations: Review the maturity of the term promissory note (~$706k due in Jan 2026) and equipment financing to ensure no covenant breaches or refinancing needs arise.